Prognostic Value of Preoperative Plasma Von Willebrand Factor Levels in Patients with Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most frequently occurring cancer among the primary astrocytomas. We investigated the plasma von Willebrand Factor (VWF) level and its effect on the prognosis of GBM patients. This descriptive study was conducted on 50 patients with GBM. Patient's GCS score and performance rate of each patient in one year (two 6-month periods) were recorded. The mean age of the patients was 42 years, and 56% of them were male. The mean GCS scores at baseline, after six, and twelve months were 13, 13, and 11, respectively, indicating a decreasing trend during one year. The mortality rate after six months was 14%. Most of the patients had VMF levels of 220-230 and 260-270 IU/dL. After six months based on plasma VWF level, the highest mortality happened at 290-310 and 310-320 IU/dL, and all deaths occurred at 270-350 IU/dL levels. Based on the results of this study, it can be concluded that the survival of patients with GBM reduces with increasing plasma VWF level, and this level can be effective in better clinical diagnosis and prognosis of GBM.